Clear Street analyst Kaveri Pohlman raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $70 from $45 and keeps a Buy rating on the shares. The firm has increased confidence in sonelokimab’s ability to deliver equal or better outcomes in the upcoming Izar-2 trial following UCB’s positive Phase 3b results demonstrating statistically significant superiority of Bimzelx versus Skyrizi . Bimzelx’s superiority over Skyrizi underscores the central role of anti-IL17 agents in PsA-a disease, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright
- MoonLake Immunotherapeutics price target raised to $11 from $10 at Goldman Sachs
- MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer
- Sonelokimab: Strong HS and AxSpA Data, Clear Regulatory Path Support Best‑in‑Class Potential and Buy Rating
- MoonLake Highlights Positive S-OLARIS Data and Investor Day